Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding

Blood

Volumn 118, Issue 19, 2011, Pages 5302-5311

  Revenko, Alexey S ^a   Gao, Dacao ^a   Crosby, Jeff R ^a   Bhattacharjee, Gourab ^a   Zhao, Chenguang ^a   May, Chris ^a   Gailani, David ^b   Monia, Brett P ^a   MacLeod, A Robert ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; FERRIC CHLORIDE; MESSENGER RNA; PLASMA KALLIKREIN; PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLOOD LEVEL; BRAIN ISCHEMIA; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MESENTERIC ARTERY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; THROMBOGENESIS; THROMBOSIS; THROMBUS; VEIN THROMBOSIS;

EID: 81155133305     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355248     Document Type: Article

References (49)

1. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310-1312.
2. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964;202:498-499.
3. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24(6):1015-1022. (Pubitemid 38737825)
4. Gailani D, Renne T. The intrinsic pathway of coagulation: A target for treating thromboembolic disease? J Thromb Haemost. 2007;5(6):1106- 1112.
5. Schmaier AH, McCrae KR. The plasma kallikreinkinin system: Its evolution from contact activation. J Thromb Haemost. 2007;5(12):2323-2329. (Pubitemid 350154338)
6. Renne T, Gailani D. Role of factor XII in hemostasis and thrombosis: Clinical implications. Expert Rev Cardiovasc Ther. 2007;5(4):733-741. (Pubitemid 47050183)
7. Girolami A, Candeo N, De Marinis GB, Bonamigo E, Girolami B. Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation. J Thromb Thrombolysis. 2011;31(1):57-63.
8. Girolami A, Allemand E, Bertozzi I, Candeo N, Marun S, Girolami B. Thrombotic events in patients with congenital prekallikrein deficiency: A critical evaluation of all reported cases. Acta Haematol. 2010;123(4):210-214.
9. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation. 2010;121(13):1510-1517.
10. Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009; 206(11):2381-2395.
11. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19):3981- 3989.
12. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281. (Pubitemid 351213410)
13. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281. (Pubitemid 41043823)
14. Rosing J, Tans G, Griffin JH. Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. Eur J Biochem. 1985;151(3):531-538. (Pubitemid 16215785)
15. Griffin JH. Role of surface in surface-dependent activation of hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A. 1978;75(4): 1998-2002. (Pubitemid 8335471)
16. Baker BF, Lot SS, Condon TP, et al. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNAlevel and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem. 1997;272(18):11994-12000. (Pubitemid 27202775)
17. Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006; 4(9):1982-1988. (Pubitemid 44226778)
18. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: A novel anti-thrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684- 4692.
19. Wang X, Hsu MY, Steinbacher TE, Monticello TM, Schumacher WA. Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction. Thromb Res. 2007;119(5):593-600.
20. Muller F, Renne T. Platelet polyphosphates: The nexus of primary and secondary hemostasis. Scand J Clin Lab Invest. 2011;71(2):82-86.
21. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513-518.
22. van der Meijden PE, Munnix IC, Auger JM, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood. 2009;114(4):881-890.
23. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6): 1143-1156.
24. Adams GN, Larusch GA, Stavrou E, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood. 2011;117(14):3929-3937.
25. Gailani D, Renne, T., Emsley, J. Factor XI and the contact system. In: The Online Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill Companies 2010. www.ommbid.com. Accessed May 2, 2011.
26. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost. 2008;6(11):1876-1883.
27. Tordai H, Banyai L, Patthy L. The pan module: The N-terminal domains of plasminogen and hepatocyte growth factor are homologous with the apple domains of the prekallikrein family and with a novel domain found in numerous nematode proteins. FEBS Lett. 1999;461(1-2):63-67. (Pubitemid 29528571)
28. Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/kinin system: A new interpretation. Int Immunopharmacol. 2002;2(13-14):1841-1849. (Pubitemid 35373925)
29. Gailani D, Neff AT. Rare coagulation factor deficiencies. In: Hoffman H BE, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, ed. Hematology, basic principles and practice. Philadelphia: Churchill Livingstone- Elsevier;2009:1939-1952.
30. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002;277(20):17962-17969. (Pubitemid 34967607)
31. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost. 2006;95(6):1003-1010. (Pubitemid 43933758)
32. LaDuca FTK. Fletcher factor deficiency, source of variation of the partial thromboplastin time. Am J Clin Pathol. 1981;75(4):626-628.
33. Turi DC, Peerschke EI. Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies. Am J Clin Pathol. 1986;85(1):43-49. (Pubitemid 16166039)
34. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113(4):936-944.
35. Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood. 2003;102(3):953-955. (Pubitemid 36917789)
36. Ratnoff OD. A quarter century with Mr. Hageman. Thromb Haemost. 1980;43(2):95-98. (Pubitemid 10063061)
37. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) fXII deficiency are probably due to associated risk factors: A study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis. 2004;17(2):139-143. (Pubitemid 39157964)
38. Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency-a study on 73 subjects from 14 swiss families. Thromb Haemost. 1999;82(4):1240-1246. (Pubitemid 29473785)
39. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia study. Br J Haematol. 1994;87(2):422-424. (Pubitemid 24204755)
40. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006; 108(13):4045-4051. (Pubitemid 44913273)
41. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost. 2007; 5(6):1143-1148. (Pubitemid 46902114)
42. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol. 1997;17(10):2103- 2106.
43. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated fXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 1998;79(1):14-18. (Pubitemid 28037048)
44. Ishii K, Oguchi S, Murata M, et al. Activated factor XII levels are dependent on factor XII 46C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects. Blood Coagul Fibrinolysis. 2000;11(3):277-284. (Pubitemid 30331808)
45. Zito F, Drummond F, Bujac SR, et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide a concentration, and risk of coronary heart disease in men. Circulation. 2000;102(17): 2058-2062.
46. Ponitz V, Brugger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW. Activated factor XII type A and B-type natriuretic peptide are complementary and incremental predictors of mortality in patients following admission with acute coronary syndrome. Blood Coagul Fibrinolysis. 2009;20(8):652-660.
47. Jone DW, Nicholls PJ, Donohoe S, Gallimore MJ, Winter M. Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost. 2002;87(3):426-430. (Pubitemid 34232483)
48. Jones DW, Gallimore MJ, MacKie IJ, Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000;110(3):721-726.
49. Gallimore MJ, Harris SL, Jones DW, Winter M. Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb Res. 2004;114(2): 91-96. (Pubitemid 39089093)